Carina Biotech
Simon Barry is currently the VP of CAR-T Manufacturing Research and Development at Carina Biotech and a Professor at Robinson Research Institute. Simon also holds positions at the University of Adelaide as an Associate Professor and Senior Research Fellow. With previous experience at companies such as Amgen and Immunex, Simon has a background in immune mechanisms and functional genomics. Simon's education includes a Ph.D. in Cell/Cellular and Molecular Biology from the National Institute for Medical Research in London, UK.
Carina Biotech
Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing. We are working to… 1. Expand the clinical indications for T cell therapies 2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Women's & Children's Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Children's Hospital in the United States.